|
Positive contributors to operational results were US sales of Tylenol and Motrin
analgesics; upper respiratory over-the-counter products; international sales of
baby care products; sales of Neutrogena and Aveeno skin care products; and
international sales of Listerine oral care products. Primary contributors to
operational sales growth were Remicade (infliximab) and Simponi (golimumab),
biologics approved for the treatment of a number of immune-mediated inflammatory
diseases; Stelara (ustekinumab), a biologic approved for the treatment of
moderate to severe plaque psoriasis and active psoriatic arthritis; Invega
Sustenna/ Xeplion (paliperidone palmitate), a once-monthly, long-acting,
injectable atypical antipsychotic for the treatment of schizophrenia in adults;
Prezista (darunavir), a treatment for HIV; Doxil (doxorubicin HCl liposome
injection)/ Caelyx (pegylated liposomal doxorubicin hydrochloride), a medication
to treat recurrent ovarian and other cancers; Velcade (bortezomib), a treatment
for multiple myeloma; and sales of new products. The strong sales results of new
products included Zytiga (abiraterone acetate), an oral, once-daily medication
for use in combination with prednisone for the treatment of metastatic,
castration-resistant prostate cancer; Xarelto (rivaroxaban), an oral
anticoagulant; the combined sales of Complera/Eviplera (emtricitabine /rilpivirine/tenofovir
disoproxil fumarate) and Edurant (rilpivirine) for the treatment of HIV and
Invokana (canagliflozin) for the treatment of adults with type 2 diabetes. Sales
results were negatively impacted by loss of exclusivity for Aciphex/ Pariet (rabeprazole),
a proton pump inhibitor for gastrointestinal disorders and Concerta
(methylphenidate HCI) for the treatment of attention deficit hyperactivity
disorder. Primary contributors to operational growth were sales from the
acquisition of Synthes, Inc. and joint reconstruction products in the
orthopaedics business; Biosense Webster’s electrophysiology products in the
cardiovascular care business; the vision care business; as well as biosurgicals
and international sales of energy products in the specialty surgery business.
http://www.pharmabiz.com/PrintArticle.aspx?aid=79924&sid=2
Lilly India & Boehringer Ingelheim India Launch 'Next
Generation' Re-Usable Insulin Pen – HumaPen SAVVIO
Eli Lilly and Company India (Lilly), a leading innovation-driven corporation,
and Boehringer Ingelheim India, the world’s 20 leading pharmaceutical companies,
recently announced the launch of HumaPen SAVVIO, an innovative insulin delivery
pen that meets the diabetics’ individual need. This latest innovation is
engineered to resemble as a small personal accessory rather than a medical
device.
HumaPen SAVVIO, an invention by Lilly, offers an extended shelf life of up to
six years after first use. It was designed following feedback from people with
diabetes who shared their aspiration to manage diabetes discreetly.
HumaPen SAVVIO, an original research product of Lilly will be co-promoted by the
Lilly-Boehringer Ingelheim alliance in India.
Announcing the launch, Edgard Olaizola, managing director, Eli Lilly and Company
India said, “The launch of HumaPen SAVVIO marks an important milestone for
Lilly, reflecting our ongoing commitment to develop ‘people-led’ innovative
solutions for diabetes. At Lilly, we recognize that people are unique and that
their insulin delivery devices should reflect their lifestyle and personality.
That’s why we developed HumaPen SAVVIO to be lightweight, portable and available
in a choice of colours. It will help to bring a greater sense of normalcy to
using insulin. We will continue to introduce innovative products to address the
unmet needs of patients amidst the growing Indian diabetes epidemic.”
Commenting on the launch, Sharad Tyagi, managing director, Boehringer Ingelheim
India said, “After the successful launch of Trajenta by the Lilly-Boehringer
Ingelheim Alliance, this is another revolutionary product for the huge diabetes
market in India. HumaPen Savvio is in line with alliance’s ongoing commitment to
provide innovative solutions for diabetes treatment. We are constantly working
towards pioneering interventions by leveraging scientific know-how and
commercial capabilities of both companies and expanding our product portfolio
for diabetes in India.”
The new HumaPen SAVVIO is short in size, lightweight, dependable, durable, easy
to use insulin pen that will improve the everyday lives of people with diabetes.
To boost the personal confidence of diabetics, the device is designed similar to
a fashionable, compact pen with durable design and will be available in a range
of colours - red, graphite, green and silver. HumaPen SAVVIO also makes dosing
easy and insulin delivery discreet, which helps insulin users feel more at ease
when using their medication.
HumaPen SAVVIO is supported by Lilly’s Diabetes Educators Service. Spread across
the country, Diabetes Educators provide education/counselling on diabetes,
nutrition, self-management, lifestyle management, hypoglycaemia and appropriate
use of injectable devices under the guidance of treating physicians.
HumaPen SAVVIO will be available in India across six metros viz. Delhi, Mumbai,
Kolkata, Chennai, Hyderabad and Bengaluru for use with 3 mL insulin cartridges
Humalog, Humalog Mix25 and Humalog Mix50 on doctor’s prescription.
http://www.pharmabiz.com/ArticleDetails.aspx?aid=79919&sid=2
|
